BeOne Medicines (ONC) vs United Therapeutics (UTHR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
United Therapeutics (UTHR) has outperformed BeOne Medicines (ONC) over the past year, gaining 19.3% versus a gain of 6.6%. Over five years, UTHR leads with a +191.3% price change compared with +1.6% for ONC. BeOne Medicines is the larger company by market cap ($41.41 billion vs $23.38 billion), about 1.8 times the size.
On valuation, United Therapeutics trades at a lower forward P/E (17.9x vs 35.5x for BeOne Medicines). United Therapeutics converts more of its revenue into profit, with a net margin of 41.9% versus 5.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ONC | UTHR |
|---|---|---|
| Share price | $364.02 | $545.00 |
| Market cap | $41.41B | $23.38B |
| 1-day change | +0.34% | +0.62% |
| YTD return | +19.82% | +11.85% |
| 1-year return | +6.56% | +19.30% |
| 5-year return | +1.56% | +191.33% |
| P/E ratio (TTM) | 65.12 | 19.52 |
| Forward P/E | 35.49 | 17.92 |
| EPS (TTM) | $5.59 | $27.92 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.34B | $3.18B |
| Revenue growth (YoY) | +40.23% | +10.61% |
| Net income (latest FY) | $286.93M | $1.33B |
| Gross margin | 87.49% | 87.92% |
| Operating margin | 8.37% | 46.89% |
| Net margin | 5.37% | 41.94% |
| 52-week high | $385.22 | $609.35 |
| 52-week low | $253.95 | $409.07 |
| Distance from 52-week high | -5.50% | -10.56% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +19.55% | +19.20% |
| Average volume | 391.40K | 649.55K |
| Shares outstanding | 104.92M | 42.89M |
| Employees | 12,000 | 1,400 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- UTHR has outperformed ONC by 12.7 percentage points over the past year.
- BeOne Medicines trades at a higher earnings multiple (65.1x vs 19.5x trailing P/E).
- United Therapeutics is more profitable, keeping 41.9 cents of every revenue dollar as net income versus 5.4 cents for BeOne Medicines.
- BeOne Medicines grew revenue faster in its latest fiscal year (+40.23% vs +10.61%).
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
About United Therapeutics
UTHR stock →United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,400 employees
ONC vs UTHR FAQ
Which is bigger, BeOne Medicines or United Therapeutics?
BeOne Medicines (ONC) is larger, with a market capitalization of $41.41B compared with $23.38B for United Therapeutics (UTHR).
Which stock has performed better over the past year, ONC or UTHR?
UTHR returned +19.30% over the past 12 months, compared with +6.56% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ONC or UTHR?
UTHR has the lower trailing P/E at 19.5, versus 65.1 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are BeOne Medicines and United Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.